KR100855149B1 - 약물 결정 형태의 변형 방법 - Google Patents

약물 결정 형태의 변형 방법 Download PDF

Info

Publication number
KR100855149B1
KR100855149B1 KR1020057013313A KR20057013313A KR100855149B1 KR 100855149 B1 KR100855149 B1 KR 100855149B1 KR 1020057013313 A KR1020057013313 A KR 1020057013313A KR 20057013313 A KR20057013313 A KR 20057013313A KR 100855149 B1 KR100855149 B1 KR 100855149B1
Authority
KR
South Korea
Prior art keywords
mycophenolate
crystal
ray powder
mycophenolate sodium
drug substance
Prior art date
Application number
KR1020057013313A
Other languages
English (en)
Korean (ko)
Other versions
KR20050096940A (ko
Inventor
자비네 페퍼
디르크 비크후젠
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100855149(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20050096940A publication Critical patent/KR20050096940A/ko
Application granted granted Critical
Publication of KR100855149B1 publication Critical patent/KR100855149B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057013313A 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법 KR100855149B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
GB0301259.8 2003-01-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077016703A Division KR20070087181A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법

Publications (2)

Publication Number Publication Date
KR20050096940A KR20050096940A (ko) 2005-10-06
KR100855149B1 true KR100855149B1 (ko) 2008-08-28

Family

ID=9951448

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020097022061A KR101129105B1 (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법
KR1020057013313A KR100855149B1 (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법
KR1020097022060A KR20090115821A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법
KR1020077016703A KR20070087181A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법
KR1020107024515A KR20100120321A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020097022061A KR101129105B1 (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020097022060A KR20090115821A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법
KR1020077016703A KR20070087181A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법
KR1020107024515A KR20100120321A (ko) 2003-01-20 2004-01-19 약물 결정 형태의 변형 방법

Country Status (32)

Country Link
US (3) US20060122265A1 (da)
EP (2) EP2308471A1 (da)
JP (1) JP4549976B2 (da)
KR (5) KR101129105B1 (da)
CN (2) CN100595199C (da)
AR (2) AR043343A1 (da)
AT (1) ATE546132T1 (da)
AU (1) AU2004206731B2 (da)
BR (1) BRPI0406827A (da)
CA (2) CA2706900A1 (da)
CL (1) CL2004000073A1 (da)
CO (1) CO5580738A2 (da)
CY (1) CY1112772T1 (da)
DK (1) DK1592401T3 (da)
EC (1) ECSP055918A (da)
ES (1) ES2382035T3 (da)
GB (1) GB0301259D0 (da)
HK (1) HK1084874A1 (da)
IL (1) IL169484A (da)
MX (1) MXPA05007691A (da)
MY (1) MY148297A (da)
NO (1) NO20053846L (da)
NZ (1) NZ541073A (da)
PE (2) PE20040826A1 (da)
PL (2) PL376525A1 (da)
PT (1) PT1592401E (da)
RU (1) RU2388757C2 (da)
SG (1) SG155046A1 (da)
SI (1) SI1592401T1 (da)
TW (1) TWI325785B (da)
WO (1) WO2004064806A2 (da)
ZA (1) ZA200504442B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
CA2555454C (en) 2004-04-27 2009-12-15 Sandor Molnar Mycophenolate mofetil impurity
CN101014584A (zh) 2004-07-20 2007-08-08 特瓦药厂私人有限公司 结晶霉酚酸钠的制备方法
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US8314122B2 (en) * 2008-10-09 2012-11-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EA036793B1 (ru) * 2015-12-21 2020-12-22 Янссен Фармацевтика Нв Способ кристаллизации для получения кристаллов гемигидрата канаглифлозина
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000005360A (ko) * 1996-04-12 2000-01-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 미코페놀레이트의 장용성 약제 조성물
KR20010034917A (ko) * 1998-06-24 2001-04-25 고든 라이트 이르베사르탄의 신규한 형태, 이러한 형태를 제조하는방법 및 이를 함유하는 약학 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
CZ292423B6 (cs) 1993-09-15 2003-09-17 Syntex (U.S.A.) Inc. Krystalický, bezvodý mykofenolát mofetilu a intravenózní prostředek, ve kterém je obsažen
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000005360A (ko) * 1996-04-12 2000-01-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 미코페놀레이트의 장용성 약제 조성물
KR20010034917A (ko) * 1998-06-24 2001-04-25 고든 라이트 이르베사르탄의 신규한 형태, 이러한 형태를 제조하는방법 및 이를 함유하는 약학 조성물

Also Published As

Publication number Publication date
CA2706900A1 (en) 2004-08-05
AU2004206731A8 (en) 2004-08-05
GB0301259D0 (en) 2003-02-19
DK1592401T3 (da) 2012-05-21
PT1592401E (pt) 2012-05-10
US20060122265A1 (en) 2006-06-08
ECSP055918A (es) 2005-11-22
US20090209639A1 (en) 2009-08-20
ATE546132T1 (de) 2012-03-15
CL2004000073A1 (es) 2005-01-14
KR20090115898A (ko) 2009-11-09
TW200505505A (en) 2005-02-16
AR103711A2 (es) 2017-05-31
CA2509796C (en) 2010-09-14
KR20090115821A (ko) 2009-11-06
TWI325785B (en) 2010-06-11
MXPA05007691A (es) 2005-09-30
PL213192B1 (pl) 2013-01-31
RU2388757C2 (ru) 2010-05-10
PE20040826A1 (es) 2004-12-23
US8124795B2 (en) 2012-02-28
CY1112772T1 (el) 2016-02-10
SI1592401T1 (sl) 2012-05-31
SG155046A1 (en) 2009-09-30
EP1592401B1 (en) 2012-02-22
PL376525A1 (pl) 2006-01-09
IL169484A (en) 2016-03-31
EP2308471A1 (en) 2011-04-13
BRPI0406827A (pt) 2005-12-27
CO5580738A2 (es) 2005-11-30
EP1592401A2 (en) 2005-11-09
WO2004064806A2 (en) 2004-08-05
CN100595199C (zh) 2010-03-24
AR043343A1 (es) 2005-07-27
KR20070087181A (ko) 2007-08-27
KR20050096940A (ko) 2005-10-06
KR101129105B1 (ko) 2012-04-12
CA2509796A1 (en) 2004-08-05
ES2382035T3 (es) 2012-06-04
US8008511B2 (en) 2011-08-30
AU2004206731A1 (en) 2004-08-05
RU2005126328A (ru) 2006-07-27
IL169484A0 (en) 2007-07-04
HK1084874A1 (en) 2006-08-11
KR20100120321A (ko) 2010-11-15
ZA200504442B (en) 2006-02-22
AU2004206731B2 (en) 2008-03-20
PL393385A1 (pl) 2011-03-14
JP2006515016A (ja) 2006-05-18
WO2004064806A3 (en) 2004-10-28
CN1738605A (zh) 2006-02-22
PE20110276A1 (es) 2011-05-27
CN101333201A (zh) 2008-12-31
US20110288313A1 (en) 2011-11-24
NZ541073A (en) 2008-12-24
JP4549976B2 (ja) 2010-09-22
MY148297A (en) 2013-03-29
NO20053846L (no) 2005-08-16

Similar Documents

Publication Publication Date Title
KR100855149B1 (ko) 약물 결정 형태의 변형 방법
KR100207802B1 (ko) N-[4-(5-시클로펜틸옥시카르보닐)아미노-1-메틸인돌-3-일-메틸]-3-메톡시벤조일]-2-메틸벤젠설폰아미드 화합물 및 이것의 제조 방법
RU2468012C2 (ru) Частицы антагониста crth2
JP2005522503A (ja) Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
MXPA04007995A (es) Desolvatacion de solvatos de hemicalcio de atorvastatina.
EA014079B1 (ru) Новая полиморфная форма кристаллической гемикальциевой соли аторвастатина
AU2010200756A1 (en) Process for modifying drug crystal formation
WO2017071375A1 (zh) 一种氘代咪唑酮化合物的晶型及其制备方法和用途
RU2806322C2 (ru) Стабильная полиморфная форма 6-фтор-9-метил-9h-бета-карболина и ее применения
CN116813675B (zh) 一种化合物晶型及其制备、组合物和用途
JP2022545361A (ja) ６－フルオロ－９－メチル－９Ｈ－β－カルボリンの安定な多形形態およびその使用
WO2009060318A2 (en) Polymorphic forms of ramelteon and processes for preparation thereof
CN106061983A (zh) 吡嗪并[2,1‑c][1,2,4]三嗪化合物的晶体(1)

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120802

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20130801

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20150717

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20160720

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20170804

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20180730

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20190729

Year of fee payment: 12